Streetbeat News

Equity Actions

MOTS

Motus GI Holdings Inc (NASDAQ:MOTS) shares dropped 46% to $1.16 after announcing a public offering of approximately 3.3 million shares and warrants to raise $5.0 million. The offering includes Series A and Series B warrants with exercise prices of $1.50 per share, expiring in five and eighteen months respectively. The company aims to close the offering by December 21 and will use the proceeds for general corporate purposes and working capital. MOTS has a 52-week high of $23.39 and a 52-week low of $1.16.

Portfolio Pulse from Henry Khederian

December 19, 2023 | 3:03 pm

FTV

Fortive (NYSE:FTV), a diversified industrial technology firm, has been evaluated by analysts with mixed sentiments. The average 12-month price target among 7 analysts is $74.86, with a high of $90.00 and a low of $66.00. This target has decreased by 1.72% from the previous $76.17. Analysts' actions include both upgrades and downgrades, with ratings ranging from 'Buy' to 'Neutral'. Fortive's financial performance shows a revenue growth of 2.64% as of September 30, 2023, a high net margin of 14.59%, but lower ROE and ROA compared to industry averages, and a healthy debt-to-equity ratio of 0.27.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 3:02 pm

KMPR

Analysts have provided 4 ratings for Kemper (NYSE:KMPR) in the last quarter, with an average 12-month price target of $59.5, a decrease from the previous $64.25. The ratings include 1 bullish and 3 somewhat bullish. Analysts from Piper Sandler and Raymond James have adjusted their price targets, with JMP Securities providing the highest target of $75. Kemper's financial indicators show a negative revenue trend, below-average net margin, ROE, and ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 3:01 pm

KYMR

Kymera Therapeutics (NASDAQ:KYMR) has been evaluated by 4 analysts in the past quarter, with 1 bullish, 1 somewhat bullish, and 2 indifferent ratings. The average price target is now $29.5, down from the previous $60.00, indicating a 50.83% decline. Analysts from Wells Fargo, Morgan Stanley, Piper Sandler, and HC Wainwright & Co. have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Kymera is a biotech company focused on targeted protein degradation to treat diseases. Despite a significant decline in revenue growth and below-average ROA, the company has a strong net margin and ROE, with a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 3:01 pm

EMR

Emerson Electric (NYSE:EMR) received 7 analyst ratings in the last quarter, with an average 12-month price target of $108.43, up from the previous $107.00. Ratings include 1 bullish, 4 somewhat bullish, and 2 indifferent. Analysts from Wells Fargo, UBS, Stephens & Co., RBC Capital, Citigroup, and Keybanc have adjusted their price targets and ratings, reflecting their views on the company's market position, revenue growth, net margin, ROE, ROA, and debt management. Emerson Electric operates in automation equipment and services, with significant interests in AspenTech and a former National Instruments business.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 3:01 pm

FDS

FactSet Research Systems Inc (NYSE:FDS) reported Q1 FY24 sales growth of 7.4% year-over-year to $542.2 million, slightly beating consensus estimates. Adjusted EPS was $4.12, marginally above the $4.11 consensus. The company saw a net increase of 24 clients, with adjusted operating margin contracting due to higher technology expenses. FactSet repurchased shares and declared a quarterly dividend. However, it lowered its FY24 revenue and EPS outlook, leading to a 1.22% decline in its stock price.

Portfolio Pulse from Lekha Gupta

December 19, 2023 | 2:48 pm

BDRX

Biodexa Pharmaceuticals PLC-ADR (NASDAQ:BDRX) shares plummeted by 31.7% to $2.07 after announcing the pricing of a public offering at significant discounts. The offering includes Class A Units at $2.00 each and Class B Units at $1.9999, both with warrants exercisable at $2.20. The offering is expected to close around December 21, subject to standard conditions.

Portfolio Pulse from Henry Khederian

December 19, 2023 | 2:44 pm

BNTX

CVAC

EWG

CureVac N.V. announced that the German Federal Patent Court denied the validity of its patent EP 1 857 122 B1 after a nullity action by BioNTech SE. This decision does not impact other ongoing litigation in Germany involving seven other CureVac intellectual property rights. CureVac plans to appeal the decision at the German Federal Court of Justice. The company remains confident in its intellectual property portfolio and its contributions to mRNA COVID-19 vaccines. The scheduled ruling on infringement of the patent by BioNTech's Comirnaty is likely to be postponed.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:39 pm

AAPL

MSFT

NVDA

QQQ

QQQM

The Nasdaq 100 Index reached a new all-time high of 16,772.71, marking a 53% YTD increase and its best annual performance since the 1999 tech boom. The Invesco QQQ Trust ETF (QQQ) and Invesco NASDAQ 100 ETF (QQQM) also hit new highs. Apple (AAPL), Microsoft (MSFT), and NVIDIA (NVDA) are the top gainers, contributing significantly to the index's returns.

Portfolio Pulse from Surbhi Jain

December 19, 2023 | 2:34 pm

PRSR

Shareholders of Prospector Capital Corp. (PRSR) have voted to approve the business combination with LeddarTech Holdings. The record date for the issuance of one additional Prospector Class A Share for each non-redeemed share will be on the closing date of the transaction.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:32 pm